PERTH, Australia – On the heels of positive phase IIb data, Melbourne-based Opthea Ltd. announced a private placement of AU$50 million (US$33.87 million) from institutional investors in Australia and the U.K. to advance lead candidate OPT-302 to phase III trials in wet age-related macular degeneration (AMD).
IFM Therapeutics LLC, an innate immunity specialist that's quickly sparked major deals with big pharma, is stoking the generative fire at its heart with $55.5 million in new financing led by Boston-based Omega Funds. The Boston-based company will use the funds to launch as many as three new subsidiaries, starting with IFM Quattro and a new incubator, IFM Discovery.
Radiologist burnout is a common problem. To combat this issue, Berkeley, Calif.-based Rad AI has launched with a $4 million seed round led by Gradient Ventures, Google's AI-focused venture fund. Other participants in the round were UP2398, Precursor Ventures, GMO Venture Partners, Array Ventures, Hike Ventures, Fifty Years VC and various angels.
RSS
